Israel’s Scinai Immunotherapeutics has announced successful preclinical trial results of its innovative anti‑IL‑17 VHH antibody (‘NanoAb’) as a local treatment for the large and underserved population of patients with mild to moderate plaque psoriasis.
Successful trial for plaque psoriasis treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.